MovDisordV3, PascalFrancis, Curation, bibRecord, 000105

Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease

Identifieur interne : 000105 ( PascalFrancis/Curation ); précédent : 000104; suivant : 000106

Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease

Auteurs : E. H. Aylward [États-Unis] ; A.-M. Codori [États-Unis] ; A. Rosenblatt [États-Unis] ; M. Sherr [États-Unis] ; J. Brandt [États-Unis] ; O. C. Stine [États-Unis] ; P. E. Barta [États-Unis] ; G. D. Pearlson [États-Unis] ; C. A. Ross [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2000.

RBID : Pascal:00-0269081

Descripteurs français

Pascal (Inist)
- Chorée Huntington, Noyau caudé, Imagerie RMN, Atrophie, Etude longitudinale, Exploration, Evolution, Homme, Asymptomatique.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Asymptomatic, Atrophy, Caudate nucleus, Evolution, Exploration, Follow up study, Human, Huntington disease, Nuclear magnetic resonance imaging.

Abstract

Previous research by our group demonstrated a longitudinal change in caudate volume for symptomatic subjects with Huntington's disease (HD), and suggested that volume of the caudate may be a useful outcome measure for therapeutic studies in symptomatic patients. The current study was designed to determine whether longitudinal change in caudate atrophy could be documented in presymptomatic carriers of the HD gene mutation, and to compare rate of change in these subjects with rate of change in mildly and moderately affected symptomatic patients. We measured caudate volumes on serial magnetic resonance image scans from 30 patients at three stages of HD: 10 presymptomatic; 10 with mild symptoms, as indicated by scores on the Quantified Neurological Exam (QNE) ≤35; and 10 with moderate symptoms (QNE >45). The mean interscan interval was 36 months. When analyzed separately, both symptomatic groups and the presymptomatic group demonstrated a significant change in caudate volume over time. Amount of change over time did not differ significantly among the three groups. We conclude that change in caudate volume may be a useful outcome measure for assessing treatment effectiveness in both presymptomatic and symptomatic subjects.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 15`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease`
A11	`01`	`1`		`@1 AYLWARD (E. H.)`
A11	`02`	`1`		`@1 CODORI (A.-M.)`
A11	`03`	`1`		`@1 ROSENBLATT (A.)`
A11	`04`	`1`		`@1 SHERR (M.)`
A11	`05`	`1`		`@1 BRANDT (J.)`
A11	`06`	`1`		`@1 STINE (O. C.)`
A11	`07`	`1`		`@1 BARTA (P. E.)`
A11	`08`	`1`		`@1 PEARLSON (G. D.)`
A11	`09`	`1`		`@1 ROSS (C. A.)`
A14	`01`			`@1 Division of Psychiatric Neuroimaging, Johns Hopkins University School of Medicine @2 Baltimore, Maryland @3 USA @Z 1 aut. @Z 7 aut. @Z 8 aut.`
A14	`02`			`@1 Division of Neurobiology, Johns Hopkins University School of Medicine @2 Baltimore, Maryland @3 USA @Z 1 aut. @Z 3 aut. @Z 4 aut. @Z 6 aut. @Z 9 aut.`
A14	`03`			`@1 Departments of Radiology and Psychiatry, University of Washington @2 Seattle, Washington @3 USA @Z 1 aut.`
A14	`04`			`@1 Division of Medical Psychology, Department of Neuroscience, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine @2 Baltimore, Maryland @3 USA @Z 2 aut. @Z 5 aut.`
A14	`05`			`@1 Joint Appointment with School of Hygiene and Public Health, Department of Neuroscience, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine @2 Baltimore, Maryland @3 USA @Z 8 aut.`
A14	`06`			`@1 Joint Appointment with Department of Neuroscience, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine @2 Baltimore, Maryland @3 USA @Z 9 aut.`
A20				`@1 552-560`
A21				`@1 2000`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000087348900190`
A44				`@0 0000 @1 © 2000 INIST-CNRS. All rights reserved.`
A45				`@0 38 ref.`
A47	`01`	`1`		`@0 00-0269081`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Previous research by our group demonstrated a longitudinal change in caudate volume for symptomatic subjects with Huntington's disease (HD), and suggested that volume of the caudate may be a useful outcome measure for therapeutic studies in symptomatic patients. The current study was designed to determine whether longitudinal change in caudate atrophy could be documented in presymptomatic carriers of the HD gene mutation, and to compare rate of change in these subjects with rate of change in mildly and moderately affected symptomatic patients. We measured caudate volumes on serial magnetic resonance image scans from 30 patients at three stages of HD: 10 presymptomatic; 10 with mild symptoms, as indicated by scores on the Quantified Neurological Exam (QNE) ≤35; and 10 with moderate symptoms (QNE >45). The mean interscan interval was 36 months. When analyzed separately, both symptomatic groups and the presymptomatic group demonstrated a significant change in caudate volume over time. Amount of change over time did not differ significantly among the three groups. We conclude that change in caudate volume may be a useful outcome measure for assessing treatment effectiveness in both presymptomatic and symptomatic subjects.
C02	`01`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Chorée Huntington @5 01`
C03	`01`	`X`	`ENG`	`@0 Huntington disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Corea Huntington @5 01`
C03	`02`	`X`	`FRE`	`@0 Noyau caudé @5 04`
C03	`02`	`X`	`ENG`	`@0 Caudate nucleus @5 04`
C03	`02`	`X`	`SPA`	`@0 Núcleo caudado @5 04`
C03	`03`	`X`	`FRE`	`@0 Imagerie RMN @5 07`
C03	`03`	`X`	`ENG`	`@0 Nuclear magnetic resonance imaging @5 07`
C03	`03`	`X`	`SPA`	`@0 Imageria RMN @5 07`
C03	`04`	`X`	`FRE`	`@0 Atrophie @5 10`
C03	`04`	`X`	`ENG`	`@0 Atrophy @5 10`
C03	`04`	`X`	`SPA`	`@0 Atrofia @5 10`
C03	`05`	`X`	`FRE`	`@0 Etude longitudinale @5 16`
C03	`05`	`X`	`ENG`	`@0 Follow up study @5 16`
C03	`05`	`X`	`SPA`	`@0 Estudio longitudinal @5 16`
C03	`06`	`X`	`FRE`	`@0 Exploration @5 17`
C03	`06`	`X`	`ENG`	`@0 Exploration @5 17`
C03	`06`	`X`	`SPA`	`@0 Exploración @5 17`
C03	`07`	`X`	`FRE`	`@0 Evolution @5 18`
C03	`07`	`X`	`ENG`	`@0 Evolution @5 18`
C03	`07`	`X`	`SPA`	`@0 Evolución @5 18`
C03	`08`	`X`	`FRE`	`@0 Homme @5 20`
C03	`08`	`X`	`ENG`	`@0 Human @5 20`
C03	`08`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`09`	`X`	`FRE`	`@0 Asymptomatique @5 23`
C03	`09`	`X`	`ENG`	`@0 Asymptomatic @5 23`
C03	`09`	`X`	`SPA`	`@0 Asintomático @5 23`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Maladie héréditaire @5 42`
C07	`06`	`X`	`ENG`	`@0 Genetic disease @5 42`
C07	`06`	`X`	`SPA`	`@0 Enfermedad hereditaria @5 42`
C07	`07`	`X`	`FRE`	`@0 Encéphale @5 45`
C07	`07`	`X`	`ENG`	`@0 Brain (vertebrata) @5 45`
C07	`07`	`X`	`SPA`	`@0 Encéfalo @5 45`
C07	`08`	`X`	`FRE`	`@0 Imagerie médicale @5 53`
C07	`08`	`X`	`ENG`	`@0 Medical imagery @5 53`
C07	`08`	`X`	`SPA`	`@0 Imageneria medical @5 53`
N21				`@1 185`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002C16

Links to Exploration step

Pascal:00-0269081

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease</title>
<author><name sortKey="Aylward, E H" sort="Aylward, E H" uniqKey="Aylward E" first="E. H." last="Aylward">E. H. Aylward</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Psychiatric Neuroimaging, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurobiology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Departments of Radiology and Psychiatry, University of Washington</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Codori, A M" sort="Codori, A M" uniqKey="Codori A" first="A.-M." last="Codori">A.-M. Codori</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Medical Psychology, Department of Neuroscience, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Rosenblatt, A" sort="Rosenblatt, A" uniqKey="Rosenblatt A" first="A." last="Rosenblatt">A. Rosenblatt</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurobiology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Sherr, M" sort="Sherr, M" uniqKey="Sherr M" first="M." last="Sherr">M. Sherr</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurobiology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Brandt, J" sort="Brandt, J" uniqKey="Brandt J" first="J." last="Brandt">J. Brandt</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Medical Psychology, Department of Neuroscience, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Stine, O C" sort="Stine, O C" uniqKey="Stine O" first="O. C." last="Stine">O. C. Stine</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurobiology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Barta, P E" sort="Barta, P E" uniqKey="Barta P" first="P. E." last="Barta">P. E. Barta</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Psychiatric Neuroimaging, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Pearlson, G D" sort="Pearlson, G D" uniqKey="Pearlson G" first="G. D." last="Pearlson">G. D. Pearlson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Psychiatric Neuroimaging, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Joint Appointment with School of Hygiene and Public Health, Department of Neuroscience, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Ross, C A" sort="Ross, C A" uniqKey="Ross C" first="C. A." last="Ross">C. A. Ross</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurobiology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Joint Appointment with Department of Neuroscience, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0269081</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0269081 INIST</idno>
<idno type="RBID">Pascal:00-0269081</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002C16</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000105</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease</title>
<author><name sortKey="Aylward, E H" sort="Aylward, E H" uniqKey="Aylward E" first="E. H." last="Aylward">E. H. Aylward</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Psychiatric Neuroimaging, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurobiology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Departments of Radiology and Psychiatry, University of Washington</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Codori, A M" sort="Codori, A M" uniqKey="Codori A" first="A.-M." last="Codori">A.-M. Codori</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Medical Psychology, Department of Neuroscience, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Rosenblatt, A" sort="Rosenblatt, A" uniqKey="Rosenblatt A" first="A." last="Rosenblatt">A. Rosenblatt</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurobiology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Sherr, M" sort="Sherr, M" uniqKey="Sherr M" first="M." last="Sherr">M. Sherr</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurobiology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Brandt, J" sort="Brandt, J" uniqKey="Brandt J" first="J." last="Brandt">J. Brandt</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Medical Psychology, Department of Neuroscience, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Stine, O C" sort="Stine, O C" uniqKey="Stine O" first="O. C." last="Stine">O. C. Stine</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurobiology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Barta, P E" sort="Barta, P E" uniqKey="Barta P" first="P. E." last="Barta">P. E. Barta</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Psychiatric Neuroimaging, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Pearlson, G D" sort="Pearlson, G D" uniqKey="Pearlson G" first="G. D." last="Pearlson">G. D. Pearlson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Psychiatric Neuroimaging, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Joint Appointment with School of Hygiene and Public Health, Department of Neuroscience, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Ross, C A" sort="Ross, C A" uniqKey="Ross C" first="C. A." last="Ross">C. A. Ross</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurobiology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Joint Appointment with Department of Neuroscience, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Asymptomatic</term>
<term>Atrophy</term>
<term>Caudate nucleus</term>
<term>Evolution</term>
<term>Exploration</term>
<term>Follow up study</term>
<term>Human</term>
<term>Huntington disease</term>
<term>Nuclear magnetic resonance imaging</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Chorée Huntington</term>
<term>Noyau caudé</term>
<term>Imagerie RMN</term>
<term>Atrophie</term>
<term>Etude longitudinale</term>
<term>Exploration</term>
<term>Evolution</term>
<term>Homme</term>
<term>Asymptomatique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Previous research by our group demonstrated a longitudinal change in caudate volume for symptomatic subjects with Huntington's disease (HD), and suggested that volume of the caudate may be a useful outcome measure for therapeutic studies in symptomatic patients. The current study was designed to determine whether longitudinal change in caudate atrophy could be documented in presymptomatic carriers of the HD gene mutation, and to compare rate of change in these subjects with rate of change in mildly and moderately affected symptomatic patients. We measured caudate volumes on serial magnetic resonance image scans from 30 patients at three stages of HD: 10 presymptomatic; 10 with mild symptoms, as indicated by scores on the Quantified Neurological Exam (QNE) ≤35; and 10 with moderate symptoms (QNE >45). The mean interscan interval was 36 months. When analyzed separately, both symptomatic groups and the presymptomatic group demonstrated a significant change in caudate volume over time. Amount of change over time did not differ significantly among the three groups. We conclude that change in caudate volume may be a useful outcome measure for assessing treatment effectiveness in both presymptomatic and symptomatic subjects.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>15</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>AYLWARD (E. H.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CODORI (A.-M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ROSENBLATT (A.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SHERR (M.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BRANDT (J.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>STINE (O. C.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>BARTA (P. E.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>PEARLSON (G. D.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>ROSS (C. A.)</s1>
</fA11>
<fA14 i1="01"><s1>Division of Psychiatric Neuroimaging, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Division of Neurobiology, Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Departments of Radiology and Psychiatry, University of Washington</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Division of Medical Psychology, Department of Neuroscience, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Joint Appointment with School of Hygiene and Public Health, Department of Neuroscience, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Joint Appointment with Department of Neuroscience, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>552-560</s1>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000087348900190</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2000 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>38 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>00-0269081</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Previous research by our group demonstrated a longitudinal change in caudate volume for symptomatic subjects with Huntington's disease (HD), and suggested that volume of the caudate may be a useful outcome measure for therapeutic studies in symptomatic patients. The current study was designed to determine whether longitudinal change in caudate atrophy could be documented in presymptomatic carriers of the HD gene mutation, and to compare rate of change in these subjects with rate of change in mildly and moderately affected symptomatic patients. We measured caudate volumes on serial magnetic resonance image scans from 30 patients at three stages of HD: 10 presymptomatic; 10 with mild symptoms, as indicated by scores on the Quantified Neurological Exam (QNE) ≤35; and 10 with moderate symptoms (QNE >45). The mean interscan interval was 36 months. When analyzed separately, both symptomatic groups and the presymptomatic group demonstrated a significant change in caudate volume over time. Amount of change over time did not differ significantly among the three groups. We conclude that change in caudate volume may be a useful outcome measure for assessing treatment effectiveness in both presymptomatic and symptomatic subjects.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Chorée Huntington</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Huntington disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Corea Huntington</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Noyau caudé</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Caudate nucleus</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Núcleo caudado</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Imagerie RMN</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nuclear magnetic resonance imaging</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Imageria RMN</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Atrophie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Atrophy</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Atrofia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Etude longitudinale</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Follow up study</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estudio longitudinal</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Exploration</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Exploration</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Exploración</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Evolution</s0>
<s5>18</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Evolution</s0>
<s5>18</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Evolución</s0>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Asymptomatique</s0>
<s5>23</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Asymptomatic</s0>
<s5>23</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Asintomático</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie héréditaire</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Genetic disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad hereditaria</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Brain (vertebrata)</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Imagerie médicale</s0>
<s5>53</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Medical imagery</s0>
<s5>53</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Imageneria medical</s0>
<s5>53</s5>
</fC07>
<fN21><s1>185</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000105 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000105 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:00-0269081
   |texte=   Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease

Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri